This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary RTKs Therapeutic Antibody Development
Background of RTKs
Overexpression and mutations of RTKs can lead to the activation of signaling pathways, promoting unlimited proliferation and survival of various types of cancer cells. Therefore, RTKs therapeutic antibodies may offer new strategies in the treatment of companion animal cancers. BioVenic provides veterinary RTKs therapeutic antibody development services, encompassing the entire process required for various antibody development techniques, helping to offer new perspectives in the treatment of companion animal cancers.
Background of RTKs
| Full Name | Receptor tyrosine kinases |
|---|---|
| Aliases | TKR, TRK, Trk. |
| Target Profile | RTKs belong to the cell surface receptor family that specifically binds growth factors, hormones, cytokines, neurotrophins, and other ligands, then influencing cellular behaviors. They consist of three structural domains: an extracellular (N-terminal), a transmembrane, and a cytoplasmic kinase domain. |
MoA of RTKs
RTKs undergo phosphorylation upon ligand binding, activating Ras, which then triggers the activation of Raf. Raf phosphorylates MEK, further activating ERK. Simultaneously, Raf stimulates MAP3 kinases, which in turn sequentially activate JNK1/2, p38, and ERK5. Additionally, the autophosphorylation of RTKs triggers PI3K activation, subsequently activating Akt. This activation then stimulates mTOR within the mTORC1 complex, and this process is further modulated by the mTORC2 complex. And PLCγ activation leads to Ca2+ release and PKC activation. Mutations affecting these RTK signaling pathways are commonly observed in various malignancies, leading to increased tumor cell proliferation and invasion.
Fig.1 Schematic diagram of RTK and downstream pathways.1,2
Application in Veterinary Therapeutics
RTKs are activated through the autophosphorylation of tyrosine residues, triggering downstream signaling pathways like Ras/MAPK, PI3K/Akt, and PLCγ, which regulate cell proliferation and survival. Dysregulation of RTKs is closely linked to cancer development and progression, such as canine breast cancer, osteosarcoma, lymphoma, feline vaccine-associated sarcoma, and so on. RTK antibodies targeting specific RTKs associated with the growth of certain cancers in canine and feline can effectively slow down tumor progression and even induce cancer cell death.
Veterinary RTKs Therapeutic Antibody Development Services
Uncontrolled proliferation of tumor cells can occur due to dysfunctional RTKs without proper regulation. RTK antibodies specifically bind to particular RTKs, inhibiting their activity and interrupting signaling pathways crucial for controlling cancer cell proliferation and survival. BioVenic offers veterinary RTKs therapeutic antibody development services, covering the entire process from initial antibody preparation to validation. We also design and synthesize species-specific antibodies targeting RTKs, aiding in the development of veterinary therapeutic antibodies with high affinity and low immunogenicity.
Please click the link below for more information about our veterinary RTKs therapeutic antibody development services.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
BioVenic utilizes emerging antibody preparation technologies, including hybridoma, single B cell, and phage display techniques, and optimizes the development process to ensure the high activity of the antibodies.
We implement strict quality control measures throughout the veterinary therapeutic antibody development process, ensuring the stability and batch consistency of the antibody samples.
Our antibody development services are not limited to a single species. By developing species-specific antibodies, we aim to provide safer treatment applications for companion animals like canine and feline.
RTKs play a pivotal role in the development of various companion animal cancers. Researching and developing therapeutic antibodies targeting RTKs contribute to offering new perspectives in the treatment of companion animal cancers. BioVenic provides veterinary RTKs therapeutic antibody development services, offering full-cycle support. If you require these services, please do not hesitate to contact us!
References
- Regad, Tarik. "Targeting RTK signaling pathways in cancer." Cancers 7.3 (2015): 1758-1784.
- Image retrieved from Figure 1 "Schematic representation of Receptor Tyrosine Kinase and downstream signaling pathways." Regad, Tarik., 2015, used under [CC BY 4.0], the image title was changed to "Schematic diagram of RTK and downstream pathways."